Sacubitril/Valsartan
Brand name: Entresto
Rank #12 of 500 drugs by total cost
$1.30B
Total Cost
1,220,812
Total Claims
$1.30B
Total Cost
23,453
Prescribers
$1,066
Cost per Claim
239,316
Beneficiaries
1,994,160
30-Day Fills
$55K
Avg Cost/Provider
52
Avg Claims/Provider
About Sacubitril/Valsartan
Sacubitril/Valsartan (sold as Entresto) was prescribed 1,220,812 times by 23,453 Medicare Part D providers in 2023, costing the program $1.30B. At $1,066 per claim, this is a high-cost medication.
💰 This drug alone accounts for 0.5% of all Medicare Part D drug spending.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 9 | Fluticasone/Umeclidin/Vilanter (Trelegy Ellipta) | $1.81B | 2,046,216 |
| 10 | Dapagliflozin Propanediol (Farxiga) | $1.65B | 1,666,200 |
| 11 | Sitagliptin Phosphate (Januvia) | $1.54B | 1,567,668 |
| 12 | Sacubitril/Valsartan (Entresto) | $1.30B | 1,220,812 |
| 13 | Bictegrav/Emtricit/Tenofov Ala (Biktarvy) | $1.29B | 310,738 |
| 14 | Etanercept (Enbrel Sureclick) | $1.12B | 145,737 |
| 15 | Enzalutamide (Xtandi) | $985.0M | 72,710 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology